These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1674 related articles for article (PubMed ID: 16674999)

  • 1. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.
    Wein L; Wein S; Haas SJ; Shaw J; Krum H
    Arch Intern Med; 2007 Jul; 167(14):1476-86. PubMed ID: 17646601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis.
    Själander A; Jansson JH; Bergqvist D; Eriksson H; Carlberg B; Svensson P
    J Intern Med; 2008 Jan; 263(1):52-60. PubMed ID: 18088252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
    Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H
    Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboprophylaxis and early antithrombotic therapy in patients with acute ischemic stroke and cerebral venous and sinus thrombosis.
    Busch M; Masuhr F
    Eur J Med Res; 2004 Apr; 9(4):199-206. PubMed ID: 15210400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
    Harenberg J; Huisman MV; Tolle AR; Breddin HK; Kirchmaier CM
    Semin Thromb Hemost; 2001 Oct; 27(5):513-8. PubMed ID: 11668421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism prophylaxis and treatment in patients with acute stroke and traumatic brain injury.
    Vergouwen MD; Roos YB; Kamphuisen PW
    Curr Opin Crit Care; 2008 Apr; 14(2):149-55. PubMed ID: 18388676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low molecular weight heparin for deep vein thrombosis in glioma patients.
    Schmidt F; Faul C; Dichgans J; Weller M
    J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.
    Mismetti P; Laporte-Simitsidis S; Tardy B; Cucherat M; Buchmüller A; Juillard-Delsart D; Decousus H
    Thromb Haemost; 2000 Jan; 83(1):14-9. PubMed ID: 10669147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of unfractionated heparin and low molecular weight heparin in pulmonary thromboembolism: meta-analysis].
    Zhai ZG; Wang C; Liu YM; Qin ZQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):221-6. PubMed ID: 15266820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
    Haas S
    Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing venous thromboembolism in medical patients.
    Leizorovicz A; Mismetti P
    Circulation; 2004 Dec; 110(24 Suppl 1):IV13-9. PubMed ID: 15598642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
    DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis of thrombosis with low-molecular-weight heparin (LMWH).
    Holzheimer RG
    Eur J Med Res; 2004 Mar; 9(3):150-70. PubMed ID: 15096326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.